Hsbc Holdings PLC Has $5.45 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Hsbc Holdings PLC lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 161.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 87,498 shares of the company's stock after purchasing an additional 53,970 shares during the period. Hsbc Holdings PLC owned 0.26% of TransMedics Group worth $5,452,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Stifel Financial Corp increased its holdings in TransMedics Group by 20.8% in the fourth quarter. Stifel Financial Corp now owns 8,968 shares of the company's stock valued at $559,000 after purchasing an additional 1,544 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $245,000. State of Tennessee Department of Treasury acquired a new stake in TransMedics Group in the fourth quarter valued at $830,000. Tower Research Capital LLC TRC increased its holdings in TransMedics Group by 1,602.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock valued at $272,000 after purchasing an additional 4,103 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in TransMedics Group by 296.8% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 11,070 shares of the company's stock valued at $690,000 after purchasing an additional 8,280 shares during the period. Institutional investors own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on TMDX shares. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $90.19 on Tuesday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market cap of $3.05 billion, a price-to-earnings ratio of 95.95 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm's 50-day simple moving average is $74.67 and its 200 day simple moving average is $77.10.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.